At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 646 enrolled
Drug / intervention
fluticasone furoate/vilanterol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder Delivered Once Daily Via a Dry Powder Inhaler Compared With Placebo in Subjects of Asian Ancestry With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 3 clinical trial evaluating fluticasone furoate/vilanterol and Placebo for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 646 participants across 34 sites in 4 countries.
Detailed Summary
The purpose of the study is to investigate the efficacy and safety of fluticasone furoate/vilanterol Inhalation Powder compared with placebo over a 24 weeks treatment period in subjects of Asian ancestry with Chronic Obstructive Pulmonary Disease (COPD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesChina, Philippines, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedJun 2011
Primary CompletionSep 2012
TodayJul 2026
First PostedJun 20, 2011
Enrollment StartApr 1, 2011
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.0 years ago
Interventions
fluticasone furoate/vilanteroldrug
Inhaled corticosteroid/long acting beta-agonist
Placebodrug
matching placebo